Stockreport

Is This Gene-Editing Stock Doomed? [The Motley Fool]

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF Investors had high expectations of the first clinical trial to edit the DNA of living humans, but they came away with concerns. Sangamo Therapeutics ( NASDAQ [Read more]